source
- Pain drugmaker Latigo outlines plans to go publicThe Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.BioPharma Dive · 10d ago↗ source
- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…BioSpace · 10d ago↗ source
- STAT+: The next step of site-neutral, and a fiery PBM hearingMedicare proposes to reduce payments to hospitals for certain drugs and imaging services.STAT · 10d ago